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column-passed fractions at day 21. In summary our data show
that by increasing the starting purity of CD4Foxp3CD27
cells a greater expansion of the Treg population can be
achieved, making it more feasible to obtain clinically useful
doses of Treg for immunotherapy protocols to prevent or treat
GVHD. Rapamycin at doses of 5-10 ng/mL inhibits the expan-
sion of cells without the phenotype and function of Tregs, but
higher doses (50-200 ng/mL) are toxic to Tregs.
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TREATMENT OF STEROID REFRACTORY, SEVERE ACUTE GRAFT VERSUS
HOST DISEASE WITH EXPANDED MESENCHYMAL STEM CELLS IN CHIL-
DREN HAVING UNDERGONE ALLOGENEIC STEM CELL TRANSPLANTA-
TION: A SINGLE CENTER EXPERIENCE
Ball, L.M.1, Kollen, W.J.W.1, Lankester, A.1, Roleofs, H.2,
Fibbe, W.E.2, Egeler, R.M.1 1Dept. Pediatrics, Leiden University Med-
ical Center, Leiden, RC, Netherlands; 2Immunohematology and Stem
Cell Research, Leiden University Medical Center, Leiden, RC, Nether-
lands.
Despite advances in pre-transplant immune suppression and do-
nor HLA typing methods acute graft versus host disease (aGvHD)
remains a signiﬁcant problem following allogeneic HSCT. Steroid
therapy is the treatment of choice in severe aGvHD. Steroid
non-responsive aGvHD is associated with increased morbidity and
more importantly death due to organ damage and/or infection
related to the use of continuing immune suppression. Second line
treatments continue to be evaluated. Whatever their initial effects,
presently they have had little impact on overall survival.
Mesenchymal stem cells (MSCs) are poor antigen presenting
cells, not expressing MHC class II or co-stimulatory molecules.
They down regulate allo-reactive T cell responses when added to
mixed lymphocyte cultures. MSCs alter cytokine excretion proﬁles
of dendritic cells, naı¨ve and effector T cells, and NK cells inducing
a more tolerant phenotype.
MSCs have been used successfully in a child with resistant
aGvHD (le Blanc. Lancet 2004).
We conducted an ethically committee approved prospective
phase I/II study of co-infusion of expanded MSCs for treatment of
children with steroid refractory, grade II-IV aGVHD.
MSCs, isolated from parental donor marrow were expanded
under GMP conditions. MSCs either as haploidentical or 3rd party.
Patient characteristics receiving MSCs for steroid refractory GvHD.
LUMC 2005-2006
UPN 1 UPN 2 UPN 3 UPN 4
Male Male Male Female
MDS RC Omens Fanconi
anemia
JMML
12y, 3mo 1 yr, 4mo 6yr, 10mo 1yr, 7mo
Sibling ID ORD ID x 2 Matched UD
BMT
Matched Cord
Blood
GvHD 4
(Skin/GI/
Liver)
4 GI
acute/chronic
plus
CMV/graft
failure
4 (skin/GI/
Liver)
4 GI plus AdV
Steroid/CSA/
Tacrolimus/
MMF
Steroid/
Tacrolimus/
MMF
Steroid/CSA/
Anti TNF	/
anti CD25
Steroid/
Tacrolimus/
MMF
MSC1 3rd
party
MSC2 haplo MSC1 3rd
party
MSC2 3rd party
1.1  106/kg 1.8  106/kg 2.3  106/kg 1.76  106/kg
Male 33 years Female 25 years Male 33 years Female 25 years
2 infusions 2 infusions 2 infusions 2 infusions
430 CR No response 430 CR 430 CR
Died
Klebsilella
sepsis
Died
CMV/GvHD
Alive Limited
cGvHD
skin
Alive small
bowel fibrosis
UPN 5 UPN 6 UPN 7 UPN 8
Male Female Male Female
Kostmaan
syndrome
EBV induced
HLH
MDS RC MDS RC
monosomy 7
3yr, 10mo 6yr, 4mo 13yr, 2 mo 4yr, 2mo
Matched UD
BMT
Cord Plus Haplo
and MM UD
BMT
MUD x 3,
DLI’s
MM Cord blood
4GI acute/
chronic
4 Liver 4 (Skin/GI/
Liver)
4 (Skin/GI/Liver)
AdV
Steroid/CSA/
Anti TNF	/
anti CD25
Steroid/CSA/
Tacrolimus
Steroid/MMF Steroid/CSA/
Tacrolimus
MSC3 3rd
party
MSC2 3rd party MSC1 3rd
party
MSC4 3rd party
1.7 106/kg 2.0 106/kg 1.2  106/kg 2.2  106/kg
Female 35
years
Female 25 years Male 33 years Male 36 years
2 infusions 1 infusion 2 infusions 2 infusions
PR; relapsed
GvHD
Not evaluated 430 CR 430 CR
Died
infection/
GvHD
Died EBV
reactivation
Alive liver
dysfunction
Alive
UPN - Unique patient number; CR - complete response: PR -
partial response; AdV - adenovirus; CMV - cytomegalovirus;
EBV - Epstein Barr virus; HLH - hemaphagocytic lymphohis-
tiocytosis; MDS RC - myelodysplastic syndrome and refractory
cytopenia; JMML - Juvenile myelomonocytic leukemia; CSA -
cyclosporine
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BLOCKING LFA-1 ACTIVATION WITH LOVASTATIN PREVENTS GRAFT-
VERSUS-HOST DISEASE IN MOUSE BONE MARROW TRANSPLANTATION
Wang, Y.1, Li, D.1, Jones, D.1, Bassett, R.1, Sale, G.E.2, Khalili, J.1,
Komanduri, K.V.1, Couriel, D.P.1, Champlin, R.E.1, Molldrem, J.J.1,
Ma, Q.1 1University of Texas M.D. Anderson Cancer Center, Houston,
TX; 2Fred Hutchinson Cancer Research Center, Seattle, WA.
Leukocyte function associated antigen-1 (LFA-1) regulates T cell
adhesion and activation. LFA-1 is constitutively expressed on cell
surface in an inactive state. The control of LFA-1 activation is
critical in inﬂammatory and immune responses. We demonstrated
previously that the I-domain, the ligand binding site of LFA-1,
changes from the low-afﬁnity state to high-afﬁnity state upon
activation. Therapeutic antagonist, such as lovastatin, stabilizes the
I-domain in the low-afﬁnity state and inhibits the LFA-1 activa-
tion. Here, we report that lovastatin can block mouse T cell
adhesion and proliferation in vitro. First, we demonstrated that
lovastatin treatment reduced the mortality and morbidity in the
mouse GVHD model. Lovastatin treatment signiﬁcantly decreased
GVHD mortality with 80% mice survived over 28 days, whereas
more than 70% of the control mice died within the ﬁrst 10 days,
and the p values was 0.045. There were signiﬁcantly reduced tissue
damages in the skin, intestine and liver of lovastatin-treated mice.
Second, we found lovastatin treatment reduced donor T cell hom-
ing to lymph nodes. There was a 65% reduction of CD4 T cells
homing to lymph nodes in lovastatin treatment group compared to
control. The reduction of CD8 T cells was greater with about
76% less cells homing to lymph nodes in the lovastatin treatment
group. Third, we found lovastatin treatment reduced donor-de-
rived T cell proliferation in vivo. There were 37% CD4 and 31%
CD8 T cells remained undivided in the lymph nodes of the
control mice at day 4 post-transplant. The lovastatin-treated mice
had reduced proliferation kinetics of both CD4 and CD8 T
cells with about 55% and 42% remained undivided. In the control
lymph nodes, there were 42% CD4 and 59% CD8 T cells
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proliferated beyond 5th and 6th cell-divisions respectively, whereas
the lovastatin treatment reduced the number to 31% and 48%
respectively. In summary, we demonstrated here that lovastatin
prevents both homing and proliferating of donor-derived T cells in
the secondary lymphoid organs, which are crucial sites for allo-
reactive expansion. While most of the control mice died of acute
GVHD within the ﬁrst week of post-transplant when alloreactive
T cells inﬁltrated the targeted organs, lovastatin treatment pre-
vented the activation and expansion of donor-derived T cells, and
thus reduced the GVHD mortality and morbidity. Our study
provides rationale for a potential novel treatment for GVHD.
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EXPRESSION OF STAT1 DURING GRAFT-VERSUS-HOST DISEASE
(GVHD)
Ziegler, J.A.1, Lokshin, A.2, Bedeir, A.3, Sepulveda, A.3, Lentzsch, S.1,
Mapara, M.Y.1 1University of Pittsburgh Cancer Institute, Pittsburgh,
PA; 2University of Pittsburgh,Luminex Facility, Pittsburgh, PA; 3Uni-
versity of Pittsburgh, Department of Pathology, Pittsburgh, PA.
The role of the IFN-g in the development of GVHD is enig-
matic due to an abundance of partially contradicting results.
Whereas there is evidence that GVHD can occur in the absence of
IFN-g, it has been demonstrated in preclinical BMT models that
IFN-g may accelerate or mitigate GVHD depending on the ex-
perimental setting. We have focused on the role of STAT1 in the
development of GVHD, the major signaling pathway of IFN-g.
We studied STAT1 and p-STAT1 (Tyr701) expression by immu-
nohistochemistry in the GVHD target organs liver, small bowel
and colon following induction of GVHD and correlated these
ﬁndings with the presence of lamina propria (LP) lymphocytes,
typical features of GVHD-induced tissue damage and expression of
tissue cytokines/chemokines. GVHD was induced in the fully
MHC mismatched BALB/c to B6 strain combination following
lethal irradiation with 975 rad. As detected by western blots p-
STAT1 expression became detectable on day 1 in the spleen and
on days 3 in the liver, small bowel and colon. Compared to
untreated controls immunohistochemical p-STAT1 staining be-
came apparent on day 3 post-BMT in the small bowel and colon
of syngeneic controls and GVHD animals. Whereas p-STAT1
expression was only transient in syngeneic controls, a further in-
crease in p-STAT1 staining was observed in GVHD animals in the
colon and small bowel on day 6. In the colon this signiﬁcant
increase in crypt cell p-STAT1 staining was associated with the
presence of LP inﬁltrating lymphocytes and coincided with the
maximal features of tissue damage (luminal sloughing, crypt de-
struction and crypt apoptosis). In line with these results IFN-g
protein expression became detectable in colon tissue lysates on day
6 supporting the role of IFN-g producing inﬁltrating donor T
cells in causing STAT1 activation and tissue damage. We conclude
that in comparison to untreated controls STAT1 activation can be
observed in the colon and small bowel starting on day 3 in
animals with GVHD and syngeneic controls. Whereas pSTAT1
staining peaks at day 3 in syngeneic controls and declines there-
after, maximal STAT1 activation occurs in GVHD animals on day
6 , coincides with detectable IFN-g expression and is accompa-
nied by LP inﬁltration and features of severe GVHD-related tissue
damage. To fully understand the role of IFN-g in the development
of gut GVHD further studies are warranted to delineate the role of
STAT1 dependent and independent signaling pathways in the
development of GVHD.
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THE PREDICTIVE VALUE OF GENE EXPRESSION PROFILES FOR ACUTE
GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANS-
PLANTATION WITH NONMYELOABLATIVE CONDITIONING FOR HEMA-
TOLOGICAL MALIGNANCY
Masmas, T.N.1, Friis-Hansen, L.2, Petersen, S.L.1, Schjerling, C.K.2,
Hansen, F.C.2, Vindelov, L.L.1 1Allogeneic Hematopoietic Cell Trans-
plantation Laboratory, Department of Hematology, Rigshospitalet,
Copenhagen, Denmark; 2Department of Clinical Biochemistry, Rigshos-
pitalet, Copenhagen, Denmark.
Purpose: To test the hypothesis that global gene expression
proﬁles of peripheral blood mononuclear cells (PBMNC) day 14
after hematopoietic cell transplantation (HCT) with nonmyeloab-
lative conditioning could predict the later occurrence of acute
graft-versus-host disease (aGVHD) grade II-IV.Material:Ninety-
eight patients with hematological malignancies received HCT with
peripheral blood stem cells from an HLA-identical sibling/mother
donor (N64/1) or from a matched unrelated donor (N33)
following nonmyeloablative conditioning with low dose ﬂudara-
bine and 2 Gy of total body irradiation. Post-transplant immuno-
suppression consisted of cyclosporine and mycophenolate mofetil.
Among these patients, 16 patients never experiencing aGVHD and
16 patients experiencing aGVHD grade II-IV before day 70
(range 21-70) were selected.Methods: RNA was precipitated from
frozen PBMNC from day 14 post-transplant and gene proﬁling
analyses were performed using Human Genome U133 Plus 2.0
GeneChip Array. The array data were normalized and GCMA
modelled in R, log2 transformed, corrected for batch variation, and
subsequently imported into dChip for further analysis. Results:
The diffentially regulated gene expression between the two groups
was identiﬁed and formed the basis for the subsequent principal
component analysis. This separated more than 85% of patients
who experienced aGvHD from those who did not. Conclusion:
Albeit preliminary, these data suggest that pattern of gene expres-
sion proﬁles early post-transplant seems to be able to predict
patients with high risk of later occurrence of aGVHD from those
never experiencing aGVHD in this retrospective study. This
knowledge could be exploited to increase the immunosupression
and thus prevent aGVHD in patients at risk. Furthermore, this
method could help identify candidate genes of interest for the
pathogenesis of aGVHD.
312
DENDRITIC CELL TYPE 2 COUNTS ON DAY 28 IN HLA-MATCHED
RELATED ALLOGENEIC PBSCT PREDICTS THE INCIDENCE OF ACUTE
AND CHRONIC GVHD
Rajasekar, R.1, Mathews, V.1, Lakshmi, K.M.1, Viswabandya, A.1,
George, B.1, Chandy, M.1, Srivastava, A.1 1Christian Medical College,
Vellore, Tamil Nadu, India.
Dendritic cells (DC) are antigen-presenting cells involved in
induction and regulation of immune responses. We investigated
the impact of the number of infused and engrafted (day 28) den-
dritic cells, DC1 (lin-HLA-DRCD11c) and DC2 (lin-HLA-
DRCD123), on the development of acute and chronic GVHD.
68 patients who underwent HLA matched related G-CSF mobi-
lized allogeneic PBSCT were included in the analysis. The median
age was 28 years (range: 3-55) and there were 43 (63%) males.
Conditioning regimen was myeloablative in 34 (Bu/Cy20; Cy/
TBI  14) and reduced intensity in the rest (Flu/Mel 12; Flu/Cy
15; Flu/Cy/ATG 3; Flu/Bu/Cy1; Flu1; Ida/Flu/Cyto-
sine2). All patients received cyclosporine and short course meth-
otrexate as GVHD prophylaxis. 23 patients developed acute
GVHD (grade II-IV) and 21 patients had chronic GVHD. Twelve
patients received steroids before day 28 for treatment of GVHD.
Seven patients died before day 28 and were excluded from the
analysis; 2 of these patients had acute GVHD. On a univariate
analysis day-28 total DC, DC1 and DC2 were signiﬁcantly asso-
ciated with development of acute and chronic GVHD while graft
total DC, DC1 and DC2 did not show a similar association. Using
a ROC curve plot analysis, cutoff values for day-28 DC (Total
DC10.7/ul, DC19.7/ul and DC2  4.5/ul) gave the highest
likelihood ratios for acute GVHD (2.77, 2.14and 3.29 respec-
tively). These cut off values signiﬁcantly discriminated patients
probability of developing acute and chronic GVHD on a univariate
analysis. On a multivariate analysis, a low day-28 DC2 (4.5/ul)
together with patient age retained their risk for acute GVHD
(HR67.74 and 1.05, P-values 0.000 and 0.042 respectively), while
for chronic GVHD only a low day-28 DC2 remained signiﬁcant
(HR12.8, P0.005). Using the DC2 cutoff value of 4.5/ul, pa-
tients were categorized into a high ( 4.5/ul) (n31) and a low
DC2 (4.5/ul) (n30) group. These two groups were comparable
with regard to age, sex, FM, conditioning regimen and graft
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